31P The IOpener study: Tyrosine kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage non-small cell lung cancer

K.D. Joode, H.J.M. Groen,M. van den Heuvel, J.S. Kloover,F. van der Meer, J.A. Stigt,C.H. van der Leest,B. Van Den Borne,R. de Wijn, D.P. Hurkmans,D.M.A. van den Heuvel,T. van Doorn, B. Pinedo,E. Kapiteijn, R. Debets, E. Verdegaal,S.H. van der Burg, J.P. Groten, J.G. Aerts, R.H. Mathijssen

Immuno-Oncology and Technology（2022）

引用 0|浏览7

暂无评分

摘要

Treatment with immune checkpoint inhibitors (ICIs) is successful, but only in a subset of patients with advanced stage non-small cell lung cancer (NSCLC). Blood-based kinase profiling of peripheral blood mononuclear cells (PBMCs) has previously shown its predictive value for response to ICI treatment in a discovery cohort (Hurkmans et al., JITC 2020). The aim of the current prospective study was to perform a blind validation of the predictive value of kinase activity profiles in PBMCs for ICI response in patients with NSCLC in a standardized setting.

查看译文

关键词

tyrosine kinase activity profiling,immune checkpoint inhibitors,lung cancer,iopener study,non-small

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要